ABSTRACT Linezolid, the first clinically available oxazolidinone antibiotic, causes potentially severe toxicities (myelosuppression, lactic acidosis, and neuropathies) ascribed to impairment of mitochondrial protein synthesis and consecutive mitochondrial dysfunction. Tedizolid, a newly approved oxazolidinone, shows an enhanced activity compared to linezolid but is also a more potent inhibitor of mitochondrial protein synthesis. We compared linezolid and tedizolid for (i) inhibition of the expression of subunit I of cytochrome c-oxidase (CYTox I; Western blot analysis), (ii) cytochrome c-oxidase activity (biochemical assay), (iii) mitochondrial oxidative metabolism (Seahorse technology), and (iv) alteration of mitochondrial ultrastructure (electron microscopy) using HL-60 promyelocytes and THP-1 monocytes exposed to microbiologically (multiples of modal MIC against Staphylococcus aureus) and therapeutically (C min Ϫ C max ) pertinent concentrations. Both drugs caused a rapid and complete (48 to 72 h) inhibition of CYTox I expression, cytochrome c-oxidase activity, and spare respiratory capacity, with conspicuous swelling of the mitochondrial matrix and loss of their cristae. Globally, tedizolid was a more potent inhibitor than linezolid. For both drugs, all effects were quickly (48 to 72 h) and fully reversible upon drug withdrawal. Using an alternation of exposure to and withdrawal from drug mimicking their approved schedule of administration (twice daily and once daily [qD] for linezolid and tedizolid, respectively), only partial inhibition of CYTox I expression was noted for up to 96 h. Thus, rapid reversal of toxic effects upon discontinuous administration may mitigate oxazolidinone toxicity. Since tedizolid is given qD, this may help to explain its reported lower preclinical and clinical toxicity.
L
inezolid (LZD), the first clinically available oxazolidinone antibiotic, inhibits bacterial protein synthesis by binding to the 23S rRNA of the large ribosomal subunit, preventing the assembly of 30S and 50S ribosomal subunits and the formation of initiation complex (1, 2). This mode of action is distinct from that of most other currently used classes acting on bacterial ribosomes, decreasing the risk of crossresistance (3). Linezolid has become over the years a valuable therapeutic option in difficult-to-treat infections by Gram-positive microorganisms where hosts' comorbidities and bacterial resistance to other agents have become problematic (see, for example, references 4, 5, 6, 7, 8, and 9) . However, linezolid usage is associated with variable incidences of potentially severe adverse reactions associated with myelosuppression (anemia and thrombocytopenia [10, 11] ), major metabolic disturbances (lactic acidosis [12, 13] ), and neuronal toxicities (peripheral and ophthalmic neuropathies [14] ). These effects, which are most commonly seen upon prolonged use of linezolid (15) and/or in patients with sustained trough levels (16) , have been suggested to result from impairment of mitochondrial protein synthesis and consecutive mitochondrial dysfunction (17, 18) . Thus, eperezolid, an early but discontinued oxazolidinone, was shown to cause time-and concentration-dependent inhibition of cell proliferation associated with a decrease in mitochondrial cytochrome c-oxidase subunit I expression, providing the first direct demonstration of mitochondria as a target for the toxic effects of this class of drugs (19) . This has been further rationalized by the high degree of homology between bacterial and mitochondrial ribosomes and the existence of common binding sites for oxazolidinones (20, 21) , explaining why derivatives with different antibacterial potencies were reported to bind to mitochondrial rRNA and to inhibit mitochondrial protein synthesis in vitro in direct relation to their antimicrobial potency (22) . This implies that the development of new oxazolidinones needs to take into account not only their intrinsic antibacterial activity (including against linezolid-resistant strains) but also their potential mitochondrial toxicity (23, 24) .
Tedizolid (formerly known as DA7157, TR700, or torezolid), is a new methyltetrazolyl oxazolidinone with enhanced activity against Gram-positive cocci (including strains carrying mobile cfr methyltransferase that confers resistance to linezolid), owing to additional target site interactions (25, 26) . However, it is also a more potent inhibitor of mitochondrial protein synthesis than linezolid in vitro (27) . Assessment of the overall mitochondrial toxicity of oxazolidinones for potential translation into the clinics should, however, not be limited to mere in vitro potency comparisons but must also take into account the conditions in which the drugs are used clinically so as to include parameters that can modulate toxicity, such as schedules of administration and actual peak and trough concentrations observed in patients. In this context, tedizolid markedly differs from linezolid in its currently approved conditions of administration (28, 29) that command a lower daily dosage and a lesser frequent schedule (200 mg once daily [qD] versus 600 mg twice daily [BID] ). The aims of the present study were to better document and compare the potentials of linezolid and tedizolid to inhibit the expression of subunit I of cytochrome c-oxidase (CYTox I), a protein encoded by the mitochondrial genome and to examine its impact on mitochondrial oxidative metabolism and morphology in cultured human cells when using concentrations pertinent of those observed in patients receiving conventional doses of these antibiotics. We used two established human cell lines representing distinct potential targets of oxazolidinone myelosuppressive toxicity, namely, (i) HL-60 promyelocytes, a leukemic cell line with commitment toward myeloid differentiation (30, 31) , and (ii) THP-1 monocytes, a leukemic cell line more differentiated as phagocytes (32) . We observed that tedizolid is a more potent mitochondrial inhibitor than linezolid. However, the inhibition exerted by both drugs on mitochondrial protein expression and metabolism can be fully reversed by drug withdrawal, suggesting a potential mitigation of toxic effects when drug concentrations fluctuate over time in patient serum. 
RESULTS
Inhibition of the expression of CYTox I and of cytochrome c-oxidase activity by oxazolidinones in HL-60 promyelocytes. In a first series of experiments, we evaluated the expression of CYTox I (one of the 13 proteins of the mitochondrial respiratory chain encoded by mitochondrial DNA [33] [28, 29, 35] ). Expression of Tom 20, a protein of the outer mitochondrial membrane encoded by the nuclear genome, was evaluated in parallel for loading control purposes. As shown in Fig. 1A , both oxazolidinones caused a concentration-dependent decrease in the expression of CYTox I, and the protein became almost undetectable for drug concentrations greater than 15 and 0.25 mg/liter for linezolid and tedizolid, respectively. Tom 20 expression was unaffected. When the expressional ratio of CYTox I to Tom 20 was plotted against oxazolidinone concentrations expressed as multiples of their modal EUCAST MIC against S. aureus, tedizolid appeared to be ϳ6-fold more inhibitory than linezolid ( Fig. 1B ; see caption for 50% inhibitory concentrations [IC 50 s] in multiples of MIC, mg/liter, and M).
Cytochrome c-oxidase activity was measured in parallel in lysates of cells subjected to the same treatments. Figure 1C shows that this activity was decreased in a concentration-dependent manner. Tedizolid was slightly more potent than linezolid, with an IC 50 1.6-fold lower than that of linezolid when concentrations were expressed as multiples of their modal EUCAST MIC against S. aureus (see caption for IC 50 s in multiples of MIC, mg/liter, and M). Figure 1D further shows a correlation between decreased cytochrome c-oxidase activity and reduced expression of CYTox I in these experiments. A significant correlation was seen for both oxazolidinones, but cytochrome c-oxidase activity decreased more rapidly with linezolid than with tedizolid for a similar decrease in CYTox I expression, illustrating differences in inhibitory potencies for CYTox I and cytochrome c-oxidase activity.
Influence of oxazolidinones on HL-60 promyelocytes proliferation and metabolic activity. In order to assess whether the effects described so far for CYTox I expression and cytochrome c-oxidase activity were the result of a general, nonspecific cytotoxicity of oxazolidinones or were specific of an effect on mitochondria, we evaluated the influence of both linezolid and tedizolid on cell proliferation (starting from an inoculum of 10 5 cells/ml) and their cytotoxicity (evaluated by their influence on metabolic activity) in HL-60 cells after 144 h of incubation over a wide range of concentrations. Results are shown in details in Fig. S1 in the supplemental material. Briefly, while the control cells population expanded by ϳ8-fold in the 6-day period, linezolid and tedizolid decreased cell expansion in a concentration-dependent manner, with 50% inhibition achieved at 74ϫ the MIC for linezolid and 5ϫ the MIC for tedizolid. Conversely, cell toxicity (taking into account the difference in cell number) became apparent only at oxazolidinone concentrations of about 30ϫ their MICs, with maximal reductions of 48 and 34% at the highest concentrations tested (200ϫ the MIC; 100 mg/liter [linezolid] and 50 mg/liter [tedizolid]).
Influence of the time of incubation with oxazolidinones on CYTox I expression and cytochrome c-oxidase activity in HL-60 promyelocytes and THP-1 monocytes. In the next series of experiments, we examined the changes of CYTox I expression over time in both HL-60 and THP-1 cells exposed to two selected concentrations of oxazolidinones (linezolid, 2.5 and 15 mg/liter; tedizolid, 0.5 and 3 mg/liter) corresponding to their respective human total C min and C max . The results are presented in Fig. 2 , with images of the actual Western blots shown in the upper panels and quantitative data shown in the lower panels. At C min , linezolid only partially decreased CYTox I expression in HL-60 cells and was almost without effect in THP-1 cells. In contrast, the protein became undetectable after 48 h of incubation with tedizolid in HL-60 cells, and its expression was reduced in a time-dependent fashion in THP-1 cells, with only 29% of its original level being detected after 120 h. At C max , both oxazolidinones caused an almost complete inhibition of CYTox I expression after 48 to 72 h in HL-60 cells. In THP-1 cells, CYTox I expression decreased slower in cells incubated with linezolid that with tedizolid, a complete inhibition being observed after 120 h versus 72 h, respectively. In contrast, the expression of SDHA (one of the four subunits of succinate dehydrogenase complex encoded by nuclear DNA) was not decreased in all these conditions (illustrated for HL-60 cells in Fig. S2 in the supplemental material) . Chloramphenicol, used as a Changes of cytochrome c-oxidase activity and mitochondrial oxygen consumption of HL-60 promyelocytes and THP-1 monocytes after 72 h of incubation at C min and C max . In these experiments, HL-60 and THP-1 cells were maintained for 72 h in the presence of linezolid or tedizolid at C min and C max , since these concentrations had proven to cause intermediate inhibitory effects at C min and maximal inhibitory effects at C max on CYTox I expression. We first measured the cytochrome c-oxidase activity (Fig.  3A) . In both cell types exposed to drugs at their C min , the cytochrome c-oxidase activity was not decreased by linezolid but was reduced to about 40% by tedizolid. At their C max , both drugs proved to be very inhibitory, leaving only about 10 to 30% of residual activity.
We then measured mitochondrial oxygen consumption using the Seahorse XF technology (see Material and Methods, Fig. S3 in the supplemental material, and reference 36). As shown in Fig. 3B , neither linezolid nor tedizolid affected basal oxygen consumption rate (OCR; considered to essentially meet cell ATP basal demand) in HL-60 cells. However, both linezolid (at C max but not at C min ) and tedizolid (at both C min and C max ) caused a marked decrease in spare capacity (denoting the inability of cells to meet an increased energy demand). Similar results were obtained with THP-1 cells. Of Table S1 in the supplemental material for definitions and a full description) in HL-60 promyelocytes (left) and THP-1 monocytes (right) incubated for 72 h in control conditions (white hatched bars) or in the presence of linezolid (LZD) (green hatched bars) or tedizolid (TZD) (red hatched bars) at total extracellular concentrations corresponding to their C min and C max (LZD, 2.5 and 15 mg/liter [28] ; TZD, 0.5 and 3 mg/liter [29, 35] , respectively). Values are shown as the percent control Ϯ the SD of triplicates for cytochrome c-oxidase activity and as means of absolute values Ϯ the standard errors of the mean (SEM) of six to eight wells for mitochondrial oxygen consumption. Statistical analysis using one-way analysis of variance (ANOVA) with Dunnett's multiple comparison of each treatment versus control was performed (ns, P Ͼ 0.05; *, P Ͻ 0.05; **, P Ͻ 0.01).
note, basal OCR and spare capacity were more elevated in THP-1 than in HL-60 cells due to their higher dependence on mitochondrial oxidative metabolism compared to aerobic glycolysis for energy supply (confirmed by observing a lower lactate release/ glucose consumption ratio than in HL-60 cells [1.
Effect of oxazolidinones on mitochondrial potential. Mitochondrial potential was measured using tetramethyl rhodamine methyl ester (TMRM [37] ). While carbonyl cyanide m-chlorophenyl hydrazine (CCCP; an uncoupling agent used as positive control) produced the expected loss of potential, no effect of oxazolidinones was noted at either C min or C max (see Fig. S4 in the supplemental material).
Electron microscopy examination of HL-60 promyelocytes and THP-1 monocytes in control conditions and after incubation with linezolid or tedizolid. Figure  4 shows the general morphology of HL-60 cells in control conditions and after incubation with linezolid or tedizolid at C max during 72 h. Compared to controls, most mitochondria in cells exposed to oxazolidinones showed a decrease in the abundance of inner membrane cristae and a swelling of the matrix (see insets), whereas outer membrane had a normal shape. Other organelles and the general morphology of the cells were otherwise unaffected. Similar observations were made in THP-1 monocytes, but alterations of mitochondrial ultrastructure were less impressive (data not shown).
Uptake of oxazolidinones by HL-60 promyelocytes and THP-1 monocytes. Since linezolid and tedizolid appeared to cause similar levels of mitochondrial toxicity when cells were exposed to concentrations corresponding to their respective C max values, we measured their total apparent concentration within HL-60 and THP-1 cells incubated for up to 72 h at these concentrations. The results are shown Table 1 . Globally, similar cellular apparent concentrations were found for both oxazolidinones at all time points, suggesting that equilibrium had been reached at or before 24 h. It is important to note that the actual tedizolid extracellular concentration (in mg/liter) was 5-fold lower than that of linezolid, indicating that the apparent accumulation of tedizolid was about four times greater on average than that linezolid. In parallel, we followed the efflux of oxazolidinones from HL-60 cells that had been incubated for 72 h with the drugs and then placed in a drug-free medium at 37°C or at 4°C for release. After 30 min, neither oxazolidinone was detectable in cell lysates whatever the temperature (which means that their apparent cellular concentrations were lower than 150 and 300 ng/ml, respectively, of the cell volumes for linezolid and tedizolid).
Reversibility of changes in CYTox I expression, cytochrome c-oxidase activity, and mitochondrial respiration in HL-60 promyelocytes. In these experiments, we explored whether the changes seen so far were reversible upon drug withdrawal. To [28] ; tedizolid, 3 mg/liter [27, 29] ). In each micrograph, one or two representative mitochondria have been selected for inclusion in the corresponding inset to illustrate the distortion of these organelles, the swelling of their matrix, and the loss of cristae in oxazolidinone-treated cells compared to control. Scale bars, 1 m (0.5 m in insets).
this effect, HL-60 were exposed for 72 h to linezolid or tedizolid at their respective C max values, washed, and reincubated in drug-free medium for up to 96 h. As shown in Fig.  5A , CYTox I expression rose to values slightly above the controls within 48 h after removal of the drug. We then examined the recovery of cytochrome c-oxidase activity and of OCR spare capacity in cells that had been incubated for 72 h at C min or C max and then reincubated for 72 h in drug-free medium. The results are shown in Fig. 5B . For cells first incubated with linezolid at C min , and for which no inhibition had been observed, no change over control values was seen. For cells first incubated with linezolid at C max or with tedizolid at either C min or C max , and for which a marked inhibition had been observed (see Fig. 3 and 4) , a return to control values was seen for cytochrome c-oxidase activity, and a rise to values higher than in controls was noted for OCR spare capacity.
Influence of an intermittent discontinuous exposure to oxazolidinones on CYTox I expression in HL-60 promyelocytes. Based on the latter set of data, we measured CYTox I expression in HL-60 exposed transiently to either linezolid or tedizolid. We took into account differences in schedules of administration and half-lives of linezolid and tedizolid in humans (linezolid, administration BID and t 1/2 ϭ 4.3 to 5.2 h [28] ; tedizolid, administration qD and t 1/2 ϭ 11 h [35] ). Thus, for linezolid, HL-60 cells were exposed to a concentration corresponding to its C max for 6 h and then transferred to linezolid-free medium for the next 6 h, and the same sequence was repeated up to 96 h (reaching a total of eight exposure/washout sequences). For tedizolid, cells were incubated at a concentration corresponding to its C max for 12 h and then transferred in tedizolid-free medium for the next 12 h, and the same sequence repeated up to 96 h (reaching a total of four exposure/washout sequences). The results are presented in Fig.  6 . For linezolid, successive exposures to the drug were without effect for the first 48 h, after which a marked inhibition of CYTox I expression was noted with only partial relief during the washout periods. After 72 h, a semistable level at about 60% of the control value was observed. For tedizolid, an inhibition of CYTox I expression to about 40% of control was observed after the first exposure but was partially relieved during washout. A semistable inhibition at about 50% of control value was observed at 72 h. Residual cell-associated concentration values were measured at the time point corresponding to the trough for each drug and were undetectable.
DISCUSSION
The potential toxicity of oxazolidinones has been recognized early in their preclinical development (23, 24, 38, 39) and its clinical impact for linezolid underlined through an abundance of case reports (see, for example, references 10, 11, 12, 14, 17, 40, 41, 42, and 43) , epidemiological studies (see, for example, references 16, 44, 45, 46, 47, and 48) , and reviews (7, (49) (50) (51) (52) , as well as through in-depth ex vivo analyses of samples from treated patients (17, 18, 42, 53) . Collectively, these studies point to mitochondria as key and selective toxicity targets in eukaryotic cells, with clear evidence of inhibition of the synthesis of proteins encoded by the mitochondrial genome being a first and probably causative event in the process leading to main long-term toxicities (see reference 54 for an early review). The present work extends and deepens these observations in several respects for linezolid and adds comparative observations for tedizolid, a newly approved oxazolidinone. First, throughout the study, we systematically used (or referred to) microbiologically and therapeutically pertinent concentrations (multiples of modal MICs toward Staphylococcus aureus [34] ; human total peak [C max ] and trough [C min ] concentrations [28, 29] ) to facilitate translation of in vitro observations to what may take place in the clinics. In this context, we observed (i) that both drugs selectively inhibit the expression of CYTox I, a protein encoded by the mitochondrial genome, but not SDHA encoded by the nuclear genome, and the activity of cytochrome c-oxidase, a key part of the . 4 ). Statistical analysis was performed using an unpaired t test for a treated versus recovered comparison under each condition (ns, P Ͼ 0.05; *, P Ͻ 0.05; **, P Ͻ 0.01, ***, P Ͻ 0.001).
mitochondrial electron chain transport; (ii) that these inhibitions are associated with the inability of mitochondria to increase their metabolic oxidative activity upon demand (spare capacity); and (iii) that these effects are fully and quickly reversible upon drug withdrawal. Globally, tedizolid-induced alterations developed at lower concentrations than for linezolid when cells were incubated continuously with the drugs, even when comparisons were made at the same multiples of their modal MICs toward S. aureus. This higher toxic potency of tedizolid cannot be ascribed to its higher apparent cellular accumulation, since, at equivalent multiples of their MIC, the two drugs reach similar cell-associated concentrations. In this respect, it is worth mentioning that we cannot exclude that part of these drugs is not truly intracellular but rather associated with the cell surface, since their efflux is rapid at both 37 and 4°C. Additional studies are also needed to determine whether expression of efflux transporters at the cell surface or whether infection would modulate oxazolidinone apparent accumulation within these cells.
Inhibition of CYTox I expression and of complex IV activity upon exposure of cultured cells to oxazolidinones is not a novel observation (see, for example, references 19 and 22) . It was also observed in samples from linezolid-treated patients (17, 18) . We show here that the inhibition of both CYTox I expression and cytochrome c-oxidase activity in cultured cells occurs rapidly upon continuous exposure to oxazolidinones (reaching almost maximal effects in 3 days). Of note, observed IC 50 values for CYTox I expression compare well with those reported for global mitochondrial protein synthesis as measured in vitro (about 9 to 14 M for linezolid [19, 22, 55] and about 0.3 M for tedizolid [27] ). The lower IC 50 of tedizolid for inhibition of CYTox I expression in comparison with those of linezolid, however, did not translate into more potent inhibition of cytochrome c-oxidase activity when the two drugs were compared at microbiologically equipotent concentrations (same multiples of MIC). This is in contrast with early studies comparing oxazolidinones with different antimicrobial potencies (22) and may denote a specific property of tedizolid. Further molecular studies are needed to unravel the mechanisms explaining this divergence. Additional studies should also be performed to understand how cells still maintain about 10 to 15% of cytochrome c-oxidase activity under conditions in which CYTox I expression is no more detectable in Western blot analysis.
Second, we showed that both linezolid and tedizolid cause a marked reduction of mitochondrial spare respiratory capacity (also called reserve capacity), which quantifies how cells respond to an increased ATP demand and withstand periods of stress (36) . Changes in this parameter are indicative of major mitochondrial dysfunctions (56, 57) that may not be apparent under basal conditions but will become manifest when ATP demand increases. In this context, unchanged basal OCR evidenced in our study probably results from the maintenance of a low but significant activity of cytochrome c-oxidase activity that may be sufficient to meet endogenous energy demand. However, the loss of spare capacity would indicate how close to their bioenergetic limits cells are operating (36) . It also heralds a loss of maximal respiration capacity usually associated with a decrease in cristae density, as we report here (see the electron microscopy studies) and was also observed in muscle biopsy specimens of a patient after prolonged use of linezolid (17) . Studies with neuronal cultured cells showed that respiratory spare capacity is essential for cell protection (58) and that its loss enhances susceptibility to stochastic mitochondrial depolarization, leading to major cell energy loss (59) . If this concept applies to HL-60 and THP-1 cells, it would explain why no mitochondrial depolarization was observed, because only a limited number of cells would be affected at any time point, making the global assay used here grossly insensitive. However, successive occurrence of stochastic effects in vivo may also explain why mitochondrial toxic effects of oxazolidinones eventually translate into overt organ toxicity (such as myelosuppressive effects) only after prolonged treatment times and why they may remain rare (such as neurotoxic effects, for which genetic predisposition may play a critical role [18, 53] ).
In a context of screening for drug safety, the combination of cytotoxicity testing using a conventional 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (60) made more specific of mitochondrial dysfunction by substituting galactose to glucose as hydrocarbon energy source (61) and of measurements of changes of mitochondrial spare capacity has been shown to be an accurate and sensitive approach for assessing the potential of in vivo mitochondrial toxicity of various molecules (62) . Using an improved global metabolic assay (MTS), we showed that mitochondrial dysfunction and inhibition of CYTox I expression develop before cytotoxicity. This seems to be in contrast with the approach proposed for drug screening mentioned above, but these studies were more focused on mitochondrial dysfunction and included large, supratherapeutic concentrations of drugs. This may conceal what is probably a concentration-dependent progression in toxic effects from mitochondrial dysfunction to proliferation impairment and then to global cytotoxicity. With respect to proliferation impairment, eperezolid was shown to cause antiproliferative effects at almost the same concentrations at which it caused inhibition of mitochondrial protein synthesis (IC 50 s of 12 and 9.5 M, respectively [19] ), whereas we found a much greater divergence between these values (30.8-and 13.8-fold for linezolid and tedizolid, respectively). Actually, the antiproliferative effect of eperezolid was much variable among cell lines (with an IC 50 up to 63 M for HEK cells [19] ), suggesting that it could be a late consequence of inhibition of mitochondrial respiration, becoming significant only after critical thresholds specific to cell types and drugs are reached. Some cultured cell lines may also be less susceptible to proliferation inhibition and to cytotoxicity related to mitochondrial dysfunction because they rely more on glycolysis than on mitochondrial metabolism for energy supply.
Third, we found that HL-60 cells were more sensitive to the inhibitory effects of oxazolidinones on protein synthesis than THP-1 cells, while THP-1 cells were slightly more sensitive to their effects on mitochondrial spare capacity. The apparent accumulation of oxazolidinones being similar in both cell types, these differences should therefore rather reflect their specific metabolic characteristics. HL-60 are less differentiated than THP-1 cells and could therefore better represent blood cells progenitors that are a possible target for oxazolidinone-induced anemia or pancytopenia (52) . On the other hand, THP-1 cells show a more oxidative metabolism, explaining why their respiratory spare capacity is more affected.
Fourth, we show here that all effects exerted by linezolid and tedizolid on mito-chondrial protein synthesis, enzyme activity, and mitochondrial respiration are fully reversible. Reversibility of the changes observed in cultured cells exposed to linezolid is not a novel observation (19) and was also noted in peripheral blood mononuclear cells of linezolid-treated patients upon drug discontinuation (18) . Interestingly enough, we document here that recovery occurs upon drug withdrawal at the same rate at which inhibition developed during exposure. This is consistent with a noncovalent binding of oxazolidinones to their target sites both in mitochondrial and in bacterial ribosomes, explaining its rapid efflux. Moreover, affinity of oxazolidinones to resting ribosomes in vitro is low (with affinity constants of around 90 to 200 M [63] ), which explains why cross-linking approaches using translation-active ribosomes were needed to map their exact site of activity (21, 64) . High-affinity binding, responsible for antimicrobial activity, is only transiently and reversibly occurring during the initiation phase of the translation process (64) . Low affinity to resting mitochondrial ribosomes would also explain why no stable association of tedizolid with mitochondria could be found by fractionation of cells incubated for short periods of time with this drug in spite of its higher accumulation in cells compared to linezolid (27) . Fifth, throughout the present and previous studies (27) , we observed that tedizolid is an as potent or even more potent inhibitor of mitochondrial protein synthesis and of oxidative metabolism than linezolid when comparing drugs at equipotent (multiples of modal MIC) and clinically pertinent (C max and C min ) concentrations. This observation was expected since tedizolid shows lower MICs than linezolid toward susceptible bacteria due to the presence of additional target site interactions at the level of the bacterial ribosomes (25) , and, therefore, presumably also for the mitochondrial ribosomes. It is also in line with the suggestion that the selection of tedizolid as clinical candidate was based more on improved intrinsic activity (including against linezolidresistant strains) than safety considerations (24) . In phase I studies (with escalating dose and treatment duration up to 21 days), tedizolid was, however, shown to cause less thrombocytopenia (65) and no clinical or subclinical neurologic or ophthalmologic changes (66) . Moreover, tedizolid, administered for 9 months to rats at doses up to 8-fold larger than its approved human use did not cause significant neuropathies, which are known to develop with linezolid under these conditions (27) . Although remaining limited in terms of dosage and treatment duration, clinical experience of tedizolid safety compares favorably with that of linezolid (67) . Interestingly enough, a recent case report suggests that tedizolid could be a useful alternative to linezolid for long-term treatments in cases of inadequate clinical tolerance, myelotoxicity or renal failure (68) . The explanation for this better-than-anticipated clinical safety profile may actually stem from the fact that mitochondrial alterations caused by oxazolidinones are reversible. Since tedizolid is administered on a once-daily schedule, it would allow for more prolonged recovery periods (see discussion in reference 27) that could mitigate its higher intrinsic toxicity compared to linezolid. Further clinical experience with longer treatment durations than currently approved are, however, needed to assess the true safety potential of tedizolid.
The present study has clear limitations. First, all comparisons were made in media with low protein content (10% serum), which minimizes drug protein binding and tends to equate free and total concentrations of linezolid and tedizolid. This could not be avoided since it is impossible to grow and maintain cells in media containing substantially larger proportions of serum. However, we know that tedizolid is 70 to 90% protein-bound in human plasma (29) versus 31% for linezolid (28) . If only the free fractions of oxazolidinones must be considered, then comparisons in our cell culture model would need to be made with lower C min and C max values for tedizolid than those used here, which would make it to appear less inhibitory than what we present. It could also be part of the explanation as to why safety clinical data for tedizolid are more favorable than anticipated based on in vitro studies. A second limitation, with respect to the development of clinically meaningful mid-and long-term toxicities, is that all experiments were made with short-term exposures. Thus, for instance, myelosuppressive effects of oxazolidinones may involve a succession of events originating in early interactions of the drugs with progenitor cells but for which clinical expression becomes only visible at the end of the differentiation/maturation process (see reference 69 for a modeling of the succession of toxic events in a pharmacokinetic-toxicodynamic context). This could be addressed in further studies, pending the development of appropriate in vitro tools.
MATERIALS AND METHODS
Drugs and cells. Tedizolid (TZD) was obtained as a microbiological standard first from Trius Pharmaceuticals (San Diego, CA) and thereafter from Cubist Pharmaceuticals GmbH (Zürich, Switzerland), now both parts of Merck & Co. (Kenilworth, NJ). Linezolid (LZD) was obtained as RX-0366-00-005 (product for in vitro investigations) from RibX Pharmaceuticals (presently Melinta Therapeutics, New Haven, CT). Chloramphenicol was obtained from Sigma-Aldrich (St. Louis, MO). Stock solutions were prepared in dimethyl sulfoxide (DMSO) and thereafter diluted in the appropriate medium to reach the desired concentration, with the DMSO final concentration in the culture fluid adjusted to 0.5% (allowing us to take into consideration a possible effect of DMSO on cell differentiation). The stability of the drugs at their free human C max was checked during 72 h of incubation in RPMI 1640 complemented or not by fetal bovine serum and in phosphate-buffered saline (PBS) using the high-pressure liquid chromatography (HPLC) assay described below. No degradation was evidenced. The human promyelocytic leukemia cells HL-60 (30, 31) and the human monocytes THP-1 (32) were obtained from the American Tissue Culture Collection (Manassas, VA) and grown in RPMI 1640 medium containing 2 g/liter glucose and 0.3 g/liter glutamine and supplemented with 10% fetal bovine serum (Gibco-Life Technologies/Thermo-Fisher Scientific, Inc., Waltham, MA). Cells were maintained at a density between 10 5 and 5 ϫ 10 5 cells/ml and incubated at 37°C in a 5% CO 2 -air atmosphere. Their proliferation was evaluated by cell counting using an automated cell counter (Beckman Coulter Life Science, Indianapolis, IN).
Preparation of a fraction enriched in mitochondria. We followed a published procedure (19) with minor modifications. In brief, cells were seeded at 2 ϫ 10 5 to 3 ϫ 10 5 cells/ml in 75-cm 2 flasks, in a total volume of 50 ml for different incubation periods and then collected, washed once with PBS, resuspended in 1 ml of TKM buffer (10 mM Tris-HCl [pH 7.5], 10 mM KCl, 0.15 mM NaCl) and homogenized with 40 strokes of the tight pestle (pestle B) of a Dounce tissue grinder (Thomas Scientific, Swedesboro, NJ). The absence of intact cells in homogenates was checked by microscopic examination. A 300-l portion of TKM buffer containing 1 M sucrose was added, and the samples were centrifuged at 1,000 ϫ g for 5 min. Supernatants were collected and centrifuged at 5,000 ϫ g for 20 min. Pellets were resuspended in a suitable volume (usually 70 to 100 l) of TKM buffer containing 0.25 M sucrose. The protein content of the fraction was determined using a bicinchoninic acid assay (BCA protein assay reagent; Pierce/Thermo Fisher, Waltham, MA).
Western blot analysis. Mitochondrial fractions were electrophoresed on precasted NuPAGE 10% Bis-Tris gels (Novex; Life Technologies/Thermo Fisher) and wet transferred to polyvinylidene fluoride membranes (Thermo Fisher), which were blocked for 1 h at room temperature with 5% dry milk in Tris-buffered saline containing 0.05% Tween 20. Membranes were then incubated overnight at 4°C (or for 1 h at room temperature) with 1 g/ml mouse anti-cytochrome c-oxidase subunit I (CYTox I) monoclonal antibody (Anti-OxPhos Complex IV subunit I monoclonal antibody; Invitrogen, catalog no. 459600 [Thermo Fisher]) or with 0.1 g/ml mouse anti-succinate dehydrogenase monoclonal antibody (AntiComplex II 70-kDa Fp subunit monoclonal antibody; Invitrogen, catalog no. 459200 [Thermo Fisher]) and then with an appropriate secondary antibody (0.08 g/ml) coupled to horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 h at room temperature. Blots were revealed using the SuperSignal West Pico chemiluminescent substrate (Thermo Fisher) and a Fuji Film FPM-100A apparatus (Fuji Films, Minato-ku, Tokyo) and CL-XPosure films (Thermo Fisher). Stripped membranes (30 min incubation at room temperature or 4°C in Restore Western blot stripping buffer; Thermo Fisher) were then incubated 1 h at room temperature with 0.02 g/ml of rabbit anti-Tom 20 polyclonal antibody (Santa Cruz Biotechnology, catalog no. FL-145) and then with an anti-rabbit IgG antibody coupled to horseradish peroxidase (Santa Cruz Biotechnology) to allow for chemiluminescence detection. The band intensity was quantified on scanned films (GelDoc; Bio-Rad, Hercules, CA) using ImageJ software (National Institutes of Health, Bethesda, MD [https://imagej.nih.gov/ij/]).
Cytochrome c-oxidase activity. Cells were seeded at 1 ϫ 10 5 to 2 ϫ 10 5 cells/ml in six-well plates, in a total volume of 6 ml for different periods of time and then pelleted by low-speed centrifugation, washed three times in PBS at 4°C, and resuspended in ice-cold water. Suspensions were sonicated (two to three times for 10 s at a maximum of 100 W; B. Braun Labsonic L; Braun Biotech International, Melsungen, Germany) and mixed with an equal volume of 0.4% digitonin. The cytochrome c-oxidase activity was assayed as previously described (70) . Briefly, a 540-mg/liter solution of cytochrome c (from bovine heart; Sigma-Aldrich, catalog no. C7752) was carefully added with sodium dithionite to achieve a 90 to 95% reduction (to avoid any excess of reducing agent) and 1.5 ml mixed with 50 l of cell lysate. Cytochrome c oxidation was followed by the decrease in its absorbance at 550 nm over 10 min (Genesys 2 spectrophotometer; Thermo Spectronic, Rochester, NY), after which complete oxidation was achieved by addition of K 3 Fe(CN) 6 in order to measure the background absorbance value of the samples. Cytochrome c-oxidase activity was calculated as the slope of the change in absorbance over time after logarithmic linearization. Data were normalized by the protein content of the cell lysate, determined by Lowry's method (71) .
Cytotoxicity assay (MTS assay). We used a CellTiter 96 AQueous nonradioactive cell proliferation assay (Promega, Madison, WI) with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-100% B in 20 min, followed by 100% B linearly over 10 min, and followed by a subsequent reequilibration at 100% A. Analytes were ionized using an electrospray ionization source operated in positive mode (spray voltage set at 5.0 kV; capillary temperature, 270°C; sheath gas flow, 40 arbitrary units). The signals were normalized using the value obtained for the corresponding internal standard. The assay was linear for concentrations ranging from 0.05 to 2.4 mg/liter for linezolid and 0.025 to 3.2 mg/liter for tedizolid. The accuracy of the method expressed as bias (in %) was determined for both linezolid and tedizolid at four concentration levels ranging from 0.1 to 1 mg/liter. The bias for the intraday accuracy were comprised between Ϫ1.37 and 1.45% (linezolid) and between 3.84 and 2.50% (tedizolid); those for interday accuracy were comprised between 0.80 and 0.76% (linezolid) and between 1.39 and 2.13% (tedizolid). The repeatability (expressed as the %CV of the data obtained on three measurements on three different days) ranged between 2.72 and 2.97% (linezolid) and between 1.04 and 3.94% (tedizolid). These values were below the limit of acceptation of 15% as recommended by the international guidelines. The limits of detection were 50 ng/ml (linezolid) and 25 ng/ml (tedizolid). Apparent cellular concentrations of oxazolidinones were calculated using a cell volume to protein ratio of 5 l/mg protein as determined experimentally in cultured cells (76) and used in our previous studies with tedizolid and THP-1 monocytes (75) .
Statistical analyses. Curve fitting and statistical analyses were performed using GraphPad Prism version 7.3 and GraphPad InStat version 3.10 both for Windows (GraphPad Software, Inc., San Diego, CA).
Source of products. Products not described above were obtained from Sigma-Aldrich or Merck KGaA (Darmstadt, Germany).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC .01599-17. Table S1 for further definition and mechanistic explanation of the successive rates of respiration measured.
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Table S1
Definition and underlying biological mechanisms of the successive OCR measured with the Agilent Seahorse XF Cell Mito Stress Test Kit. Reproduced from (3) with permission.
Rate
Definition What sets the rate of respiration
Basal respiration Respiration used to meet the endogenous ATP demand of the cell and drive proton leak pathways.
The basal rate of respiration can be set by the rate of ATP utilization, substrate availability and oxidation, or proton leak.
ATP-linked respiration
Respiration that is sensitive to oligomycin can estimate the respiration that is used to drive mitochondrial ATP synthesis.
The rate of ATP-linked respiration is largely set by the ATP demand of the cell. It can also be set by substrate supply and oxidation, particularly if there is mitochondrial dysfunction.
Proton leak Oxidative phosphorylation is incompletely coupled, as protons can leak across the inner membrane independently of ATP synthase. This leak can regulate several physiological processes.
The magnitude of oligomycin-insensitive respiration is mostly set by proton leak. Based on the experimental model and context, high leak may indicate mitochondrial injury or a normal physiological response.
Maximal respiration A titrated amount of FCCP can estimate the maximum rate of respiration. In response to protonophore addition, substrate oxidation and respiratory chain activity increase in an attempt to maintain mitochondrial membrane potential.
The rate of maximal respiration is mostly set by substrate supply and oxidation. This includes substrate transport across the plasma and mitochondrial membranes as well as rate-controlling metabolic enzymes. Changes may also reflect altered mitochondrial biogenesis or cristae density.
Reserve/Spare respiratory capacity
The reserve (or spare respiratory) capacity is the difference between the basal and maximal respiration. Broadly, this indicates the ability of a cell to meet an increased energy demand.
As a function of both the basal and maximal respiration rate, each of the factors that affect rates can also affect the reserve capacity.
Non-mitochondrial respiration
Mitochondrial respiration is blocked upon addition of electron chain inhibitors such as rotenone (Complex I) and antimycin A (Complex III).
Changes may indicate differential cell number if parallel differences appear elsewhere. In some systems, cytoplasmic oxidases are relevant (e.g. hematopoetic cells, high ROS/RNS). 
